Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course

Pediatric Infectious Disease Journal

Volumn 26, Issue 6, 2007, Pages 485-491

  Wilkesmann, Anja ^a   Ammann, Roland A ^b   Schildgen, Oliver ^a   Eis Hübinger, Anna M ^a   Müller, Andreas ^a   Seidenberg, Jürgen ^c   Stephan, Volker ^d   Rieger, Christian ^d   Herting, Egbert ^e   Wygold, Thorsten ^e   Hornschuh, Friedeman ^f   Groothuis, Jessie R ^b   Simon, Arne ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c Elisabeth Children's Hospital Medical Center   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e UNIVERSITY OF LÜBECK   (Germany)

^f UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Neuromuscular impairment; Paediatric intensive care; Prematurity; Respiratory syncytial virus

Indexed keywords

ACUTE OTITIS MEDIA; APNEA; ARTICLE; ARTIFICIAL VENTILATION; CHILD; CHILDHOOD DISEASE; CHRONIC LUNG DISEASE; CONFIDENCE INTERVAL; CONGENITAL HEART DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FEVER; GERMANY; HEALTH SURVEY; HOSPITALIZED CHILD; HUMAN; HYPOXEMIA; IMMUNE DEFICIENCY; INFECTION RISK; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEUROMUSCULAR DISEASE; PEDIATRIC HOSPITAL; PHYSICIAN; PREMATURITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK FACTOR; SEIZURE; STATISTICAL ANALYSIS; TACHYPNEA; VIRUS INFECTION; WHEEZING;

EID: 34249777543     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/INF.0b013e31805d01e3     Document Type: Article

References (32)

1. Meissner HC. Selected populations at increased risk from respiratory syncytial virus infection. Pediatr Infect Dis J. 2003;22:S40-S44; discussion S44-S45.
2. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140:543-546.
3. Meissner HC, Long SS. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112:1447-1452.
4. Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr. 2003;143:S118-S126.
5. Buckingham SC, Quasney MW, Bush AJ, DeVincenzo JP. Respiratory syncytial virus infections in the pediatric intensive care unit: clinical characteristics and risk factors for adverse outcomes. Pediatr Crit Care Med. 2001;2:318-323.
6. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532-540.
7. American Academy of Pediatrics. Policy statement: revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112:1442-1446.
8. Simon A, Khurana K, Wilkesmann A, et al. Nosocomial respiratory syncytial virus infection: impact of prospective surveillance and targeted infection control. Int J Hyg Environ Health. 2006;209:317-324.
9. Leclair JM, Freeman J, Sullivan BF, Crowley CM, Goldmann DA. Prevention of nosocomial respiratory syncytial virus infections through compliance with glove and gown isolation precautions. N Engl J Med. 1987;317:329-334.
10. Donnelly LF. Practical issues concerning imaging of pulmonary infection in children. J Thorac Imaging. 2001;16:238-250.
11. Ribes JA, Seabolt JP, Overman SB. Performance characteristics of VIDAS and directigen respiratory syncytial virus (RSV) antigen detection assays and culture for the identification of RSV in respiratory specimens. J Clin Microbiol. 2002;40:1818-1820.
12. Swierkosz EM, Flanders R, Melvin L, Miller JD, Kline MW. Evaluation of the Abbott TESTPACK RSV enzyme immunoassay for detection of respiratory syncytial virus in nasopharyngeal swab specimens. J Clin Microbiol. 1989;27:1151-1154.
13. Schildgen O, de Vries M, Jebbink M, et al. Identification of cell lines permissive for human Coronavirus NL63. J Virol Methods. In press.
14. Wilkesmann A, Schildgen O, Eis-Hubinger AM, et al. Human metapneumovirus infections cause similar symptoms and clinical severity as respiratory syncytial virus infections. Eur J Pediatr. 2006;165:467-475.
15. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-537.
16. Duppenthaler A, Ammann RA, Gorgievski-Hrisoho M, Pfammatter JP, Aebi C. Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease. Arch Dis Child. 2004;89:961-965.
17. McIntosh ED, De Silva LM, Oates RK. Clinical severity of respiratory syncytial virus group A and B infection in Sydney, Australia. Pediatr Infect Dis J. 1993;12:815-819.
18. Panitch HB. Viral respiratory infections in children with technology dependence and neuromuscular disorders. Pediatr Infect Dis J. 2004;23:S222-S227.
19. Truck J. [More than muscle stiffness]. Schweiz Rundsch Med Prax. 2006;95:501-504.
20. Smyth RL, Openshaw PJ. Bronchiolitis. Lancet. 2006;368:312-322.
21. Panitch HB. Respiratory syncytial virus bronchiolitis: supportive care and therapies designed to overcome airway obstruction. Pediatr Infect Dis J. 2003;22:S83-S87; discussion S87-S88.
22. Thorburn K, Kerr S, Taylor N, van Saene HK. RSV outbreak in a pediatric intensive care unit. J Hosp Infect. 2004;57:194-201.
23. Arnold SR, Wang EE, Law BJ, et al. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J. 1999;18:866-869.
24. Resch B, Pasnocht A, Gusenleitner W, Muller W. Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29-36 weeks gestational age. J Infect. 2005;50:397-403.
25. Resch B, Gusenleitner W, Muller WD, Haas J. Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks. Eur J Clin Microbiol Infect Dis. 2006;25:120-122.
26. Sritippayawan S, Kun SS, Keens TG, Davidson Ward SL. Initiation of home mechanical ventilation in children with neuromuscular diseases. J Pediatr. 2003;142:481-485.
27. Speer M, Cohen A, Boron M, Rankin M. Synagis outcomes registry group. Results from the 2002-2003 palivizumab outcomes registry: focus on congenital airway abnormalities and neuromuscular disease [abstract]. Pediatr Res. 2004;55.
28. Keren R, Zaoutis TE, Bridges CB, et al. Neurological and neuromuscular disease as a risk factor for respiratory failure in children hospitalized with influenza infection. JAMA. 2005;294:2188-2194.
29. Louie JK, Schechter R, Honarmand S, et al. Severe pediatric influenza in California, 2003-2005: implications for immunization recommendations. Pediatrics. 2006;117:e610-e618.
30. Schildgen O, Glatzel T, Geikowski T, et al. Human metapneumovirus RNA in encephalitis patient. Emerg Infect Dis. 2005;11:467-470.
31. Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci USA. 2005;102:12891-12896.
32. Arnold JC, Singh KK, Spector SA, Sawyer MH. Human bocavirus: prevalence and clinical spectrum at a children's hospital. Clin Infect Dis. 2006;43:283-288.